

H. Anne Pereira, PhD

EDUCATION:

BSc (Hons) Department of Pathology, University of Melbourne, Australia

PhD, Department of Pathology, University of Melbourne, Australia **PROFESSIONAL EXPERIENCE**:

2014- Present, Dean Graduate College, University of Oklahoma Health Sciences Center (OUHSC)

2009-2020, Associate Dean for Research, College of Pharmacy, OUHSC 2018-Present, David L Boren Professor, Department of Pharmaceutical Sciences, (OUHSC)

2018-2020, Herbert and Dorothy Langsam Chair in Geriatric Pharmacy 2009-2018, Professor, Department of Pharmaceutical Sciences, (OUHSC)

2009- Professor, Department of Pathology (OUHSC)

1997—2009, Associate Professor with tenure, Department of Pathology (OUHSC)

1992-1997, Assistant Professor, Department of Pathology (OUHSC)

1991-1992, Assistant Professor of Research, Microbiology and Immunology, Emory University

1984-1990, Senior Research Associate, Microbiology and Immunology, Emory University, Atlanta, GA

ENTREPRENEURIAL ACTIVITIES:

2010 - Present, Chief Scientist, Biolytx Pharmaceutical Corp, Oklahoma City, OK

2006-2010, Chairman and Chief Scientific Officer, Biolytx Pharmaceuticals Corp

2005-2006, President and Chief Scientific Officer, Biolytx Pharmaceuticals Corp

PROFESSIONAL ACTIVITIES/SOCIETY MEMBERSHIPS & HONORS:

<u>Professional activities</u>: Study Section review for American Cancer Society, American Heart Association, US Army Clinical and Rehabilitative Medicine Research Program, and NIH; Contributing Editor, Vascular Biology Publications Alert, North American Vascular Biology Organization (NAVBO), Member, Grants and Corporate Relations Committee, SLB (2012-2015); Chair Grants and Corporate Relations Committee, SLB (2015-2018); Member Professional Development Committee (2018-2020); Treasurer, SLB (2021-2024) <u>Society Memberships</u>: American Association of Colleges of Pharmacy (AACP, 2009-2024); American Association of Pharmaceutical Scientists (AAPS, 2009 – 2023); Association for Research in Vision and Ophthalmology (ARVO, 1998-2022); Society for Leukocyte Biology (SLB, 1992-present); American Society for Investigative Pathology (ASIP, 1992-2022); American Association for the Advancement of Science (AAAS, 1990-present); American Society for Microbiology, (ASM, 1986-present).

<u>Honors:</u> David L Boren Professorship (2018-present); Herbert and Dorothy Langsam Chair in Geriatric Pharmacy (2018-2020); Fellow, National Academy of Inventors (NAI, 2015-present); AAAS Fellow (2014-present); Academic Research Fellow of the American Association of Colleges of Pharmacy (2013); Henry Zarrow Presidential Professor (2008-present).

RESEARCH INTERESTS:

My background and training are in microbiology and immuno-pathology. My area of expertise is innate immunity and inflammation; in particular, the role of cationic antimicrobial peptides in host defense against infection. I was honored for my contributions to understanding innate immunity and inflammation and the application of host antimicrobial proteins against infections, by being elected a Fellow of the American Association for the Advancement of Science (AAAS). While at Emory University as a senior research associate/postdoctoral fellow I initiated the scientific investigations into the multifunctional aspects and identification of bioactive peptides based on the innate immune system molecule, CAP37. This has proven to be a productive and important area of research which I have

pursued as an independent investigator since 1992. My current studies are focused on the biological relevance and therapeutic potential of CAP37 and its bioactive peptides in severe antibiotic resistant Gram negative infections, ocular inflammation and healing, and Alzheimer's disease. The novelty of our research and its impact on the field is supported by the issuance of over 40 foreign and US patents. I was named a fellow of the National Academy of Inventors for my highly prolific spirit of innovation. These patents are licensed to Biolytx Pharmaceuticals Corporation, a University of Oklahoma startup company. I am the scientific founder of the company and I serve as the Chief Scientist.

STATEMENT OF INTEREST: I am a long-standing member of SLB, having joined while I was a postdoctoral fellow at Emory University. I have always found the Society to be a very nurturing and inclusive one that is an outstanding environment for trainees as well as established investigators. The scientific talent, high standard of presentations and camaraderie at the annual meeting are seldom encountered at other Society meetings of this size. My involvement with SLB has included the post of Treasurer from 2021 to 2024, Chair of the Grants and Corporate Relations Committee from 2015 to 2018 and member of that committee from 2012 to 2015. During the time I was Chair of the Grants and Corporate Relations Committee I was successful in obtaining NIHR13 funding to support travel awards for trainees to attend our annual meetings. As Dean of the Graduate College, I am cognizant of the importance of attendance at scientific meetings for the growth and training of our graduate students as well as our postdoctoral fellows. Mentoring of junior investigators is an important part of my daily life, having served as the Associate Dean for Research in the College of Pharmacy for over a decade and for 10 years as the core director of the pilot grant program on the NIH funded Oklahoma Shared Clinical and Translational Research (OSCTR) award. My leadership as the core director has resulted in many successes for the pilot awardees that I have had the pleasure of mentoring. Many have gone on to obtain their independent funding and garnered more than \$80.6 M in new peer reviewed grant support. I am passionate about entrepreneurship and started my biotech company based on intellectual property developed in my University Laboratory. The company is focused on the development of novel peptide therapeutics for treating severe multidrug resistant infections. I believe my long-standing research interests in neutrophils, innate immunity and inflammation, along with my commitment as a teacher, mentor, administrator and entrepreneur mesh well with the mission and vision of the Society. I look forward to making a tangible contribution to the Society if elected as President and I am eager to work with Council and the membership at large to build and advance our Society.